Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

11 July 2012 World’s First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment

King of Prussia, PA – 11 July 2012 – Findings of a first-of-its-kind study of women with von Willebrand disease (VWD) show that current postpartum treatment strategies do not increase levels of von Willebrand factor (VWF) to normal range or even to the levels of women with milder, untreated VWD. VWF is a blood protein important for preventing postpartum hemorrhage. Results of this nationwide study are being presented at the World Federation of Hemophilia 2012 World Congress in Paris. This investigator-initiated study was supported by a $1.2 million unrestricted grant from CSL Behring.

> Read More
02 July 2012 CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move

UK – 2 July, 2012 – CSL Behring UK Ltd today announce the launch of the Hizentra Dosing Calculator App at The British Society for Allergy and Clinical Immunology (BSACI) Annual Scientific Meeting, taking place in Nottingham. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Hizentra (human normal immunoglobulin, SCIg).

> Read More
27 June 2012 CSL Behring Launches New Beriplex® P/N Dosing Calculator App for Healthcare Professionals on the Move

UK – 27 June, 2012 – CSL Behring UK Ltd today announce the launch of the Beriplex P/N Dosing Calculator App at The General Anaesthetists in Training Annual Scientific Meeting, taking place in Glasgow. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Beriplex P/N (human prothrombin complex concentrate).

> Read More
27 June 2012 PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rotterdam, Netherlands — 27 June — Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

> Read More
08 June 2012 CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)

CSL Behring announced today that the company has been granted orphan drug designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine prophylaxis treatment, control and prevention of bleeding episodes, and prevention and control of bleeding in perioperative settings. CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX:CSL).

> Read More
Page 25 of 53 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+